Other Events ·
Adial Pharmaceuticals convened its 2026 Annual Meeting on September 17, 2026, where stockholders approved director…
ADILAzora Therapeutics, Inc. (DE)
Adial Pharmaceuticals convened its 2026 Annual Meeting on September 17, 2026, where stockholders approved director elections for Cary J. Claiborne and Robertson H. Gilliland, the ratification of CBIZ CPAs P.C. as auditor, an increase in authorized common shares from 100 million to 500 million, and new equity incentive plans. The meeting was adjourned regarding proposals requiring Nasdaq Listing Rule 5635(d) compliance until October 1, 2026, pending conditional exchange approval. Adial Pharmaceuticals is a biopharmaceutical company focused on developing treatments for central nervous system disorders.